At the time of writing, Anavex Life Sciences Corporation [AVXL] stock is trading at $5.30, down -0.56%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AVXL shares have gain 4.33% over the last week, with a monthly amount drifted -21.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference. In a post published today on Yahoo Finance, Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 1:30 PM (ET) on Monday, March 4th, 2024, at the Boston Marriott Copley Place in Boston, MA.
From an analyst’s perspective:
Anavex Life Sciences Corporation [NASDAQ: AVXL] stock has seen the most recent analyst activity on December 06, 2022, when Cantor Fitzgerald downgraded its rating to a Neutral and also revised its price target to $11 from $16. Previously, Berenberg started tracking the stock with Buy rating on June 23, 2022, and set its price target to $40. On September 23, 2021, BTIG Research initiated with a Buy rating and assigned a price target of $35 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $17 on December 16, 2020. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $12 as its price target on September 28, 2020. In a note dated June 18, 2019, Janney initiated an Buy rating.
For the past year, the stock price of Anavex Life Sciences Corporation fluctuated between $4.80 and $10.45. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Anavex Life Sciences Corporation [NASDAQ: AVXL] shares were valued at $5.30 at the most recent close of the market. An investor can expect a potential return of 107.55% based on the average AVXL price forecast.
Analyzing the AVXL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.3 and Total Capital is -0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.21 points at the first support level, and at 5.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.39, and for the 2nd resistance point, it is at 5.49.
Anavex Life Sciences Corporation [AVXL] reported earnings per share of -$0.11 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.14/share, meaning a difference of $0.03 and a surprise factor of 21.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.12 per share as compared to estimates of -$0.15 per share, a difference of $0.03 representing a surprise of 20.00%.
Ratios To Look Out For
It is important to note that Anavex Life Sciences Corporation [NASDAQ:AVXL] has a current ratio of 11.85. Further, the Quick Ratio stands at 11.85, while the Cash Ratio is 11.51.
Transactions by insiders
Recent insider trading involved MISSLING CHRISTOPHER U, President and CEO, that happened on Jun 28 when 0.27 million shares were sold.
